AACR 101st Annual Meeting 2010: Methods Workshops

Building and Analyzing Three-Dimensional Epithelial Cancer Models

Chairperson: Jayanta Debnath, University of California, San Francisco, CA

• Lumen formation in 3-D epithelial culture
  Jayanta Debnath
• Building 3-D models of GI cancers
  Anil K. Rustgi, University of Pennsylvania, Philadelphia, PA
• Apicobasal polarity during 3-D morphogenesis and oncogenesis
  Senthil Muthuswamy, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
• Dynamic imaging of epithelial cancers in 3-D culture
  Andrew Ewald, The Johns Hopkins University, Baltimore, MD

Clinical Trial Design in the Era of Personalized Medicine

Chairperson: Donna S. Neuberg, Dana-Farber Cancer Institute, Boston, MA

• Title to be announced
  Donna S. Neuberg
• Title to be announced
  Suzanne E. Dahlberg, Dana-Farber Cancer Institute, Boston, MA
• Title to be announced
  Powel H. Brown, UT M. D. Anderson Cancer Center, Houston, TX

Genomics and miRNAs: What’s New Under the Sun

Chairperson: George A. Calin, UT M. D. Anderson Cancer Center, Houston, TX

• Hand in hand towards future experiment shapes computation and computation guides experiments
  Isidore Rigoutsos, IBM Thomas J. Watson Research Center, Yorktown Heights, NY
• The microRNA component of transcription factors network
  Andrei Thomas-Tikhonenko, University of Pennsylvania, Philadelphia, PA
• qPCR profiling of precursor and mature miRNAS
  Thomas D. Schmittgen, The Ohio State University College of Pharmacy, Columbus, OH
• Noncoding RNAs: From scientist bench to patient bedside
  George A. Calin

Clinical Trial Design: The Challenges of Middle Development (Phase II)

Chairperson: Susan G. Groshen, USC/Norris Comprehensive Cancer Center, Los Angeles, CA

• What’s a phase II trial?
  Walter M. Stadler, University of Chicago, Chicago, IL
• Basic concepts of phase II trial design
  Richard Sposto, USC/Children’s Hospital, Los Angeles, CA
• New (or rediscovered) options in phase II trial design: Randomization and adaptation
  Daniel J. Sargent, Mayo Clinic College of Medicine, Rochester, ME

Imaging Methods for Preclinical Models of Cancer

Chairperson: James P. Basilion, Case Western Reserve University, Cleveland, OH

• Multimodal MR measurements of anticancer therapy response
  Robert J. Gillies, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
• Fluorescence lifetime imaging of tumors
  Samuel Achilefu, Washington University School of Medicine, St. Louis, MO
• Surgery with molecular navigation: Development of fluorescently labeled biological probes
  Quyen T. Nguyen, University of California San Diego, La Jolla, CA
• From a preclinical model to a clinical trial
  James P. Basilion

Nonmammalian Models of Cancer

Co-Chairpersons: Julio A. Aguirre-Ghiso, Mount Sinai School of Medicine, New York, NY, and Ross L. Cagan, Mount Sinai School of Medicine, New York, NY

• Insights into metastatic growth and dormancy using the chicken embryo system
  Julio A. Aguirre-Ghiso
• A Drosophila search for cancer mechanisms and therapeutics
  Ross L. Cagan
• Aneuploidy in zebrafish tumors caused by rp and p53 mutations
  Nancy Hopkins, Massachusetts Institute of Technology, Cambridge, MA
• Anchor cell invasion in Caenorhabditis elegans: Dissecting cell invation through basement membrane in vivo
  David R. Sherwood, Duke University, Durham, NC

Circulating Tumor Cells (CTCs) as Novel Tumor Biomarkers

Chairperson: Evi S. Lianidou, University of Athens, Athens, Greece

• Detection and characterization of CTCs: Challenges and perspectives
  Klaus Pantel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
• CTC-Chip: Isolation of circulating tumor cells
  Mehmet Toner, Harvard Medical School, Charlestown, MA
• The prognostic value of circulating tumor cells in gynecological cancers by using molecular methods
  Sabine Kasimir-Bauer, University Hospital of Essen, Essen, Germany
• CTCs in breast cancer: Advanced tools for tailored therapy?
  Massimo Cristofanilli, UT M. D. Anderson Cancer Center, Houston, TX

Clinical Trial Design: Laboratory and Translation

Chairperson: Pedro R. Lowenstein, Cedars-Sinai Medical Center, Los Angeles, CA

• Uncertainties in translating preclinical brain tumor research: Can certain failure be avoided?
  Pedro R. Lowenstein
• To know or not to know: Can Reverend Bayes rescue good science from the p value?
  Rebecca Miksad, Beth Israel Deaconess Medical Center, Boston, MA
• Preclinical models in multiple myeloma: A house built on sand?
  Keith Stewart, Mayo Clinic College of Medicine, Scottsdale, AZ
• The cult of statistical significance: How to avoid statistically significant suicide
  Stephen T. Ziliak, Roosevelt University, Chicago, IL
• A genomics perspective on how to avoid failure in clinical trials
  Spyro Mousses, Translational Genomics Research Institute, Scottsdale, AZ

Measuring the Cancer Metabolome

Chairperson: Joshua D. Rabinowitz, Princeton University, Princeton, NJ

• Overview of metabolomic technologies
  Joshua D. Rabinowitz
• Gas chromatography: Mass spectrometry (GC-MS) for cancer metabolomics
  Oliver Fiehn, University of California, Davis, CA
• Liquid chromatography: Mass spectrometry (LC-MS) for cancer metabolomics
  Christopher Beecher, University of Michigan, Ann Arbor, MI
• Nuclear magnetic resonance spectroscopy (NMR) for cancer metabolomics
  Hector Keun, Imperial College of London, London, United Kingdom

Mouse Models of Invasion and Metastasis

Chairperson: Yibin Kang, Princeton University, Princeton, NJ

• Mouse model of organ-specific metastasis
  Yibin Kang
• Models of human breast cancer metastasis in nude mice
  Janet E. Price, UT M. D. Anderson Cancer Center, Houston, TX
• Mouse models for dissecting proteases functions and tumor-stromal interactions during tumor progression
  Johanna A. Joyce, Memorial Sloan-Kettering Cancer Center, New York, NY
• New models for spontaneous metastasis of breast cancer: Cooperation between tumor and host
  Alana L. Welm, University of Utah Huntsman Cancer Institute, Salt Lake City, UT

Nanotoxicology: How to Assess Nanoparticle-Induced Toxicity

Chairperson: C. Lang Tran, Institute of Occupational Medicine (IOM), Riccarton, Edinburgh, ON, Canada

• Title to be announced
  Gunter Oberdorster, University of Rochester, Rochester, NY
• Pulmonary responses to multiwalled carbon nanotube exposure
  Vince Castranova, National Institute for Occupational Safety and Health, Morgantown, WV
• Mesothelial responses to multiwalled carbon nanotube exposure
  Roger Duffin, University of Edinburgh/Medical Research Council Centre for Inflammation Research, Edinburgh, United Kingdom
• Cardiovascular and reproductive effects of carbon nanotubes (CNT)
  Antonio Pietroiusti, Tor Vergata University, Rome, Italy

Next-Generation Sequencing: Data Analysis and Applications

Chairperson: Victor E. Velculescu, Johns Hopkins Oncology Center, Baltimore, MD

• Genome-wide catalogues of somatic mutations in individual cancers
  David Bentley, Solexa, Inc. (Illumina Cambridge), Essex, United Kingdom
• SOLiD™ sequencing with error correction codes: In pursuit of somatic mutation detection
  Kevin McKernan, Life Technologies, Beverly, MA
• An integrative genomics view of cancer biology using helicos single-molecule sequencing
  Patrice M. Milos, Helicos BioSciences Corporation, Cambridge, MA
• Complete sequencing of tumor and normal genomes
  Andrew Sparks, Complete Genomics, Inc., Mountain View, CA